[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100599575":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":24,"centralContacts":27,"locations":33,"responsibleParty":50,"collaborators":52,"id":59,"slug":24,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":60,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":24,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":79,"overallStatus":81,"whyStopped":24,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"First Affiliated Hospital of Zhejiang University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Individualized location-based Repetitive Transcranial Magnetic Stimulation","EXPERIMENTAL","Enhancing targeting accuracy through personalized target localization to improve the analgesic response rate of rTMS.",[13],"Device: Individualized location-based Repetitive Transcranial Magnetic Stimulation",{"label":15,"type":16,"description":17,"interventionNames":18},"Traditional location-based Repetitive Transcranial Magnetic Stimulation","ACTIVE_COMPARATOR","Recent studies have shown that the dorsolateral prefrontal cortex (DLPFC) plays an inhibitory role in the human pain pathway. High-frequency repetitive transcranial magnetic stimulation (rTMS) applied to the left DLPFC has been found to improve chronic migraine.",[19],"Device: Traditional location-based Repetitive Transcranial Magnetic Stimulation",[21,25],{"type":22,"name":9,"description":11,"armGroupLabels":23,"otherNames":24},"DEVICE",[9],null,{"type":22,"name":15,"description":17,"armGroupLabels":26,"otherNames":24},[15],[28],{"name":29,"role":30,"phone":31,"phoneExt":24,"email":32},"Yunze Li","CONTACT","86-13336136379","1517055@zju.edu.cn",[34],{"facility":35,"status":24,"city":36,"state":37,"zip":24,"country":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"The First Affiliated Hospital, Zhejiang University School of Medicine","Hangzhou","Zhejiang","China",{"type":40,"coordinates":41},"Point",[42,43],120.16142,30.29365,{"lat":43,"lon":42},[46],{"name":47,"role":30,"phone":48,"phoneExt":24,"email":49},"Li","+ 86（ 571） 8723 6309","zdyymzb@126.com",{"type":51,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR",[53,55,57],{"name":54,"class":6},"The Affiliated Hospital of Hangzhou Normal University",{"name":56,"class":6},"Red Cross Hospital, Hangzhou, China",{"name":58,"class":6},"The Third Affiliated hospital of Zhejiang Chinese Medical University","100599575",false,"NCT07086274","Individualized Location-based rTMS for Migraine Treatment: A Multicenter Clinical Study","Efficacy of Individualized Location-based Repetitive Transcranial Magnetic Stimulation in the Treatment of Migraine: a Prospective Clinical Study","individua rTMS","Inclusion Criteria:\n\n* Aged between 18 and 65 years; both men and women.\n* Diagnosis of migraine according to the International Classification of Headache Disorders, 3rd edition (ICHD-III), with first onset before age 50 and a history of migraine for more than 1 year.\n* Migraine frequency of ≥4 days per month during both the 3 months prior to the screening period and the screening period itself.\n* Informed consent documents are signed, and subjects are cooperative with the evaluation and rTMS treatment, having been informed of known and potential risks and available alternative treatments.\n\nExclusion Criteria:\n\n* Patients with contraindications to TMS (e.g., metal implants, pacemakers).\n* Severe anxiety or depression (HAMD score \\>35, HAMA score \\>29).\n* History of migraine prophylactic drug adjustment during the screening and treatment period.\n* Aphasia or cognitive dysfunction (MMSE score ≤23).\n* Pregnancy or lactation.\n* Clinicians assess severe comorbidities that are not treatable.","ALL","18 Years","65 Years",{"count":70,"type":71},152,"ESTIMATED","INTERVENTIONAL",[74],"NA","For migraine patients experiencing at least four attack days per month and undergoing transcranial magnetic stimulation (TMS) treatment, a randomized, double-blind controlled trial is conducted, dividing participants into a traditional targeting group and an individualized targeting group. Patients in both groups are followed up before treatment and at 1, 2, and 3 months post-treatment, evaluating the following parameters: migraine diaries, the number of migraine days, rescue medication usage, headache intensity, the number of moderate-to-severe migraine days, and the proportion of patients achieving a ≥50% reduction in migraine days. Further assessments include changes in the Migraine Disability Assessment (MIDAS), Headache Impact Test-6 (HIT-6), Migraine-Specific Quality of Life Questionnaire (MSQ), Pittsburgh Sleep Quality Index (PSQI), Patient Global Impression of Change (PGIC), 24-item Hamilton Depression Scale (HAMD-24), and 14-item Hamilton Anxiety Scale (HAMA-14). Biomarker and metabolic analyses include tryptophan and kynurenine metabolism, calcitonin gene-related peptide (CGRP), pituitary adenylate cyclase-activating polypeptide (PACAP), vasoactive intestinal peptide (VIP), neuropeptide Y (NPY), substance P, endothelin-1, inflammatory cytokines (IL-1β, IL-6, TNF-α, TGF-β1), glutamate, endocannabinoids and related lipids, as well as gut microbiota composition. Additionally, changes in resting-state functional magnetic resonance imaging (rs-fMRI) before and after treatment are analyzed. This study aims to compare the efficacy of TMS treatment under different targeting strategies in migraine patients, providing theoretical support for clinical applications.",[77,78],"Migraine","Transcranial Magnetic Stimulation Repetitive",[80],"Individualized location-based","NOT_YET_RECRUITING","2025-07-18",{"date":84,"type":85},"2025-07-25","ACTUAL",{"date":84,"type":71},{"date":88,"type":71},"2027-07-25",{"name":5,"class":6},1]